… In a mass balance study, the orally administered idelalisib dose was … the pharmacokinetics
and safety of a single 150-mg dose of idelalisib in subjects with moderate or severe hepatic …

… and safety of IDELA/GS-563117 in subjects with moderate or severe hepatic impairment
following administration of a single oral dose of IDELA. Methods: Eligible subjects categorized …

… radioactive dose administered in healthy subjects was recovered in feces (∼78%). …
pharmacokinetics and safety of IDELA and GS-563117 in subjects with moderate or severe hepatic …

… the pharmacokinetics (PK) and safety of idelalisib and GS-… subjects with severe renal
impairment and healthy subjects. … of idelalisib is predominantly mediated by the hepatic pathway …

… relevant correlations between idelalisib or GS-… subjects with moderate or severe hepatic
impairment. Overall, a single oral dose of idelalisib at 150 mg was well tolerated in subjects with …

… [4] and related to mainly hepatic toxic effects, severe diarrhea, colitis, … Yet, idelalisib has
demonstrated promising results with … associated with variable perception of safety profiles [6, 7]. …

… pharmacokinetic and pharmacodynamic properties of these novel agents to guide the reader
in the appropriate use of ibrutinib, idelalisib, … hepatic impairment, ten with moderate hepatic …

… idelalisib in patients with moderate or severe hepatic impairment were similar to those in
matched healthy individuals, … in patients with moderate or severe hepatic impairment compared …

… in IIV of idelalisib PK. In addition, a phase I study … idelalisib PK in moderate or severe
hepatic impaired subject versus healthy control subjects showed that there was only moderate …

… relapsed chronic lymphocytic leukemia (CLL) received idelalisib … of idelalisib is predominantly
mediated by the hepatic … evaluate the effects of idelalisib on the pharmacokinetics (PK) of …